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Abstract
Background: There are several high throughput approaches to identify methylated genes in cancer. We utilized
one such recently developed approach, MIRA (methylated-CpG island recovery assay) combined with CpG island
arrays to identify novel genes that are epigenetically inactivated in breast cancer.
Results: Using this approach we identified numerous CpG islands that demonstrated aberrant DNA methylation in
breast cancer cell lines. Using a combination of COBRA and sequencing of bisulphite modified DNA, we confirmed
5 novel genes frequently methylated in breast tumours; EMILIN2, SALL1, DBC1, FBLN2 and CIDE-A. Methylation
frequencies ranged from between 25% and 63% in primary breast tumours, whilst matched normal breast tissue
DNA was either unmethylated or demonstrated a much lower frequency of methylation compared to malignant
breast tissue DNA. Furthermore expression of the above 5 genes was shown to be restored following treatment
with a demethylating agent in methylated breast cancer cell lines. We have expanded this analysis across three
other common epithelial cancers (lung, colorectal, prostate). We demonstrate that the above genes show varying
levels of methylation in these cancers. Lastly and most importantly methylation of EMILIN2 was associated with
poorer clinical outcome in breast cancer and was strongly associated with estrogen receptor as well as
progesterone receptor positive breast cancers.
Conclusion: The combination of the MIRA assay with CpG island arrays is a very useful technique for identifying
epigenetically inactivated genes in cancer genomes and can provide molecular markers for early cancer diagnosis,
prognosis and epigenetic therapy.
Background
In most Western countries breast cancer is a leading
cause of cancer related deaths in women. Breast cancer
accounts for over one million of the estimated 10 million
cancers that are diagnosed globally each year in both
males and females and claimed about 375,000 deaths in
the year 2000 [1]. The use of screening mammography
and MRI has led to a decline in breast cancer-related
mortality. But these screening procedures can also lead
to overdiagnosis and false positive cases leading to unne-
cessary treatment. Therefore there is a critical need to
develop molecular biomarkers that can detect early stage
disease so that treatment can begin promptly.
Genetic as well as epigenetic changes play crucial roles
in tumour development and progression. Alterations in
DNA methylation include both genome-wide hypo-
methylation and hypermethylation events. Promoter
hypermethylation at specific gene loci is a major mechan-
ism of epigenetic inactivation in cancer cells leading to
gene silencing. A recent genome-wide study in breast
and colon cancer led to identification of tumour suppres-
sor genes that are inactivated by both genetic and epige-
netic events and importantly reduced expression of a
subset of these genes correlated with poor clinical out-
come [2]. Although the list of hypermethylated genes in
breast cancer is growing, only a few show promise as bio-
markers for early detection and risk assessment [3,4]. We
and others identified RASSF1A as one of the most highly
methylated genes in many cancer types including breast
cancer [5,6]. Identification of more genes of this type
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markers across multiple malignancies.
I nt h ep r e s e n ts t u d yw ee m p l o y e dag e n o m e - w i d e
approach to identify methylated genes in breast cancer
and further investigated these genes in other common
epithelial cancers. For the high throughput genome-
wide DNA methylation approach we utilized a very sen-
sitive assay recently developed in our laboratory (Gerd
Pfeifer lab). The methylated-CpG island recovery assay
(MIRA) is based on the high affinity of the MBD2/
MBD3L1 complex for methylated DNA and allows one
to detect cell type-dependent differences in DNA
methylation when used in combination with CpG island
arrays [7,8].
Results
Genome-wide approach identifies methylated genes in
breast cancer
We used the MIRA assay in combination with genome-
wide CpG island arrays containing 27,800 loci to identify
methylated CpG islands in 5 breast cancer cell lines
(HCC1806, HCC1419, HCC1143, HCC1937, HCC1395)
relative to normal human mammary epithelial cells
(NHMEC) [7,8]. A primary selection based on probes
showing > 5 fold enrichment of the methylated fraction
in breast cancer cell lines versus NHMEC cell line DNA
across 3 or more cell lines or a more stringent selection
with probes scoring greater than 10 in 4 or more cell
lines yielded a large number of loci showing methylation
across breast cancer cell lines (see additional 1). These
included genes/loci previously reported to be methylated
in breast cancer (for example SIM1, PAX6, DLX4,
RUNX3). In order to reduce the list to manageable
numbers we carried out bioinformatic analyses to gather
information on the expression of target genes in breast
tissue, confirmation of the presence of a CpG island
within the likely promoter region of target genes and
functional annotation to determine likely roles in
tumourigenesis, see materials and methods for more
information. This led to a selection of 32 novel genes
for further analysis (Figure 1, see additional file 2) in a
stepwise fashion including the following stages:
1. Methylation analysis in breast cancer cell lines
and normal control breast tissue DNA.
2. Methylation analysis in a panel of breast tumours
(n = 40)
3. Gene expression analysis before and after 5-aza-
dC treatment
4. Methylation analysis in an independent cohort of
paired normal/tumour breast DNA panel (n = 20)
5. Expand methylation analysis to include lung, col-
orectal and prostate cancer, for the genes showing
tumour-specific methylation in breast cancer.
Methylation analysis in breast tumours and breast
tumour cell lines
We used COBRA digest to ascertain the methylation
levels across a panel of 9 breast cancer cell lines (includ-
ing the 5 lines used for MIRA) in CpG island regions
upstream of the transcription start site. We confirmed
frequent methylation (>30%) for 16 loci in breast cancer
cell lines. These loci were unmethylated in DNA from
normal/control breast. Sixteen loci either showed low or
no methylation in the panel of breast cancer cell lines
or were equally methylated in normal control breast
DNA in the region analysed by our COBRA primers
and were removed from further analysis (Figure 1). The
remaining 16 positive genes demonstrating frequent
methylation in breast cancer cell lines were analysed
further by COBRA digest in a panel of primary breast
t u m o u r s( n=4 0 ) .N i n e( C I D E - A ,C O M P ,D B C 1 ,E M I -
LIN2, EPSTI1, FBLN2, SALL1, SESN3, SIM2) of these
genes (56%) demonstrated frequent methylation in pri-
mary breast tumours (frequency ranging from 26-63%)
(Figure 1, 2, 3, 4, 5, 6)
Expression analysis in breast tumour cell lines and
normal breast
The above nine frequently methylated genes were shown
to be expressed in normal breast tissue (Figure 2, 3, 4, 5,
6). In order to determine the role of methylation in gene
silencing, we treated breast cancer cell lines with the
demethylating agent 5-aza-dC. Eight (CIDE-A, COMP,
DBC1, EMILIN2, EPSTI1, FBLN2, SALL1, SIM2)o ft h e
above nine genes showed re-expression after treatment
of the methylated cell lines with 5aza-dC (Figure 2, 3, 4,
5, 6). Hence methylation suppressed gene expression,
whilst SESN3 showed no change in expression before
and after treatment in both methylated and unmethy-
lated cell lines. SESN3 was therefore not considered for
further analysis.
Methylation analysis in paired normal/
tumour breast cases
To determine if methylation of the eight remaining
genes was cancer-specific (i.e. tumour acquired), we ana-
lysed an independent set of paired normal/tumour
breast DNA samples (n = 20). Five genes (62.5%)
demonstrated tumour acquired methylation (EMILIN2,
SALL1, DBC1, FBLN2 and CIDE-A) (Table 1, Figures 2,
3, 4, 5, 6), whilst the remaining 3 (COMP, EPSTI1,
SIM2) showed equal methylation in the corresponding
normal breast tissue DNA. The COBRA results for
these 5 genes were confirmed by cloning and sequen-
cing of bisulphite modified DNA in primary breast
tumours (Figures 2, 3, 4, 5, 6). In majority of the breast
tumour samples we also detected the unmethylated pro-
duct. This is likely to be due to the contamination from
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sected and due to the heterogeneous nature of the pri-
mary tumour samples.
Methylation analysis in other epithelial cancers
To explore whether the above 5 genes showing
tumour-specific methylation in breast cancer were
methylated in other epithelial cancers besides breast,
we analysed a panel of cancer cell lines corresponding
to three common epithelial cancers (lung, colorectal
and prostate). Lung tumour cell lines (NSCLC) demon-
strated frequent methylation of CIDE-A, EMILN2,
FBLN2 and SALL1. DBC1 methylation in lung cancer
has been reported previously hence it was not analysed
in this study [9]. Colorectal tumour lines showed fre-
quent methylation of all 5 genes, whilst prostate
Figure 1 Stepwise analysis of 32 selected genes in breast cancer. (A) Cell line analysis confirmed frequent methylation (>30% of samples) in
cancer cell lines but not normal/control breast tissue in 16 genes (highlighted in white), which were selected for further analysis. Thirteen genes
(highlighted in light grey) did not show methylation in the region analysed by our CoBRA primers and were removed from further analysis.
Three genes (highlighted in dark grey) showed frequent methylation in cancer cell lines but also normal breast tissue and were removed from
further analysis. (B) Analysis of the 16 genes found to be frequently methylated in cell lines were analysed in primary breast cancer patient
samples. Frequent methylation (>25% of samples) was observed in nine of these genes (highlighted in white) and were carried forward for
expression analysis.
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CIDE-A, DBC1, EMILIN2, SALL1 and less frequent
methylation for FBLN2 (Table 2).
To demonstrate tumour specific methylation in other
epithelial cancers
The above genes were further analyzed in primary
tumours for the tumour types that demonstrated fre-
quent methylation in the corresponding tumour cell
lines. Where applicable N/T paired DNA was analysed
(Table 2).
EMILIN2 was methylated in 33% colorectal carcino-
mas (CRC) and in 32% adenomas, whilst only 1.2% of
corresponding normal tissues demonstrated any methy-
lation. Methylation was confirmed using cloning and
sequencing of bisulphite modified DNA (Figure 7).
Whilst NSCLC and prostate tumours were either
unmethylated or showed very low level frequency of
methylation in both tumours and corresponding nor-
mals (Table 2).
SALL1 was methylated in 83% of CRC and in 89% of
adenomas, whilst methylation frequency in correspond-
ing normals was much less (38%). SALL1 demonstrated
similar frequencies of methylation in tumour and
matched normal samples for both NSCLC and prostate
tumours (Table 2).
DBC1 was frequently methylated in CRC and prostate
cancer cell lines (we did not analyse NSCLC since
DBC1 is already known to be methylated in this cancer).
In CRC and adenomas the methylation frequency was
100% but it was not cancer specific, all corresponding
normals were also methylated. This could indicate that
Figure 2 Methylation analysis of EMILIN2. (a) The region analysed by CoBRA and sequencing is shown with CpG dinucleotides numbered and
shown in bold and BstUI and TaqaI restriction sites underlined. The position of CoBRA primers is also shown, covering the region between -407
bp and +110 bp with respect to the transcription start site. (b) CoBRA results are shown with undigested (U) PCR product next to digested (D)
PCR product for breast cancer cell lines and normal breast. (c) CoBRA results for primary breast tumours. (d) CoBRA results for breast tumour
normal pairs. (e) Selected PCR products were cloned and sequenced. Individual alleles of each of the two samples shown are represented by a
line, black and white circles represent methylated and unmethylated CpG dinucleotides respectively. The frequency of methylation within the
amplified region for each sample is indicated by the methylation index (MI). (f) EMILIN2 expression in normal breast tissue and re-expression in
methylated breast cancer cell line MDA-MB-231 following the addition of 5-aza-2’deoxycitidine is shown.
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tissues but not in others. Whilst weak methylation was
seen in 1 out of 14 prostate tumours and 2 out of 4
normals (Table 2).
FBLN2 demonstrated tumour specific methylation in
prostate tumours (36%) and was unmethylated in lung
tumours. FBLN2 similar to DBC1 demonstrated very
high frequency of methylation in colorectal tumours,
adenomas and corresponding normal samples (Table 2).
CIDE-A was found to be methylated in 7/8 analysed
primary CRC tumours and in all adenomas and corre-
sponding normals. It has been recently demonstrated
that CIDE-A expression is epigenetically controlled in
certain tissue and cell types [10], which when taken in
consideration with our methylation analysis, suggests
that normal colorectal tissue does not express CIDE-A.
Whilst a similar percentage ofm e t h y l a t i o nf r e q u e n c y
was seen in prostate tumours and corresponding nor-
mals (21% and 25% respectively). CIDE-A was methy-
lated in 1/16 NSCLC and 0/16 matched normals
(Table 2).
Methylation status and clinicopathological parameters
The most interesting finding in the breast cancer cohort
was that the methylation of EMILIN2 was associated
with relapse (P = 0.031), presence of lymph node metas-
tases (P = 0.047), with ER and PR positive tumours (P =
0.0009; 0.0082 respectively) and poor relapse free survi-
val (P = 0.041) (Figure 8). CIDE-A methylation was asso-
ciated with ER positive tumours (P = 0.016), whilst
FBLN2 methylation was associated with PR positive
tumours (P = 0.013).
Figure 3 Methylation analysis of SALL1. (a) The region analysed by CoBRA and sequencing is shown with CpG dinucleotides numbered and
shown in bold and BstUI restriction sites underlined. The position of CoBRA primers is also shown, covering the region between -338 bp and
-164 bp with respect to the transcription start site. (b) CoBRA results are shown with undigested (U) PCR product next to digested (D) PCR
product for breast cancer cell lines and normal breast. (c) CoBRA results for primary breast tumours. (d) CoBRA results for breast tumour normal
pairs. (e) Selected PCR products were cloned and sequenced. Individual alleles of each of the four samples shown are represented by a line,
black and white circles represent methylated and unmethylated CpG dinucleotides respectively. The frequency of methylation within the
amplified region for each sample is indicated by the methylation index (MI). (f) SALL1 expression in normal breast tissue and upregulation in
methylated breast cancer cell line HCC1937 following the addition of 5-aza-2’deoxycitidine is shown.
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EMILIN2 appears to be the most interesting gene due to
the association between its methylation status and clini-
cal-pathological features including survival. To confirm
that the methylation of EMILIN2 is functionally rele-
vant, we determined EMILIN2 expression in a subset of
primary breast tumours (good quality RNA was available
for these samples) using quantitative real-time RT-PCR.
Expression analysis revealed that the breast tumours
with EMILIN2 methylation showed lower levels of EMI-
LIN2 expression compared to unmethylated tumours
(Figure 9).
Discussion
Using a high throughput genome-wide approach we
have identified 5 genes showing frequent tumour
acquired methylation in breast cancer. To the best of
our knowledge methylation of EMILIN2, SALL1, DBC1,
FBLN2,o rCIDE-A has not been reported previously in
breast cancer. Furthermore we demonstrate that the
methylation is cancer specific and leads to gene
silencing. In addition we found that EMILIN2, FBLN2
and SALL1 were also frequently methylated in other
common epithelial cancers, EMILIN2 and SALL1 in col-
orectal cancer and FBLN2 in prostate cancer. To the
best of our knowledge EMILIN2 and CIDE-A methyla-
tion in primary tumours has not been previously
reported, SALL1 and FBLN2 methylation has been pre-
viously reported in acute lymphocytic leukemia [11,12]
and DBC1 methylation has been reported in NSCLC,
bladder cancer, oral cancer and in leukaemia [9,13-15].
EMILIN2 belongs to a family of extracellular matrix
(ECM) glycoproteins containing an EMI domain at the
N-terminus and a gC1q domain at the C-terminus.
EMILIN2 has been shown to suppress growth of cancer
cells [16] and triggers apoptosis in cancer cells via the
extrinsic apoptosis pathway following EMILIN2 binding
to the trail receptors DR4 and DR5.
CIDE-A belongs to a novel family of cell death indu-
cing DFF45 (DNA fragmentation factor-45) like effector
proteins. In humans there are three family members
(CIDE-A, CIDE-B, CIDE-C). In cell lines overexpression
Figure 4 Methylation analysis of DBC1. (a) The region analysed by CoBRA and sequencing is shown with CpG dinucleotides numbered and
shown in bold and BstUI restriction sites underlined. The position of CoBRA primers is also shown, covering the region between +743 and +245
with respect to the transcription start site. (b) CoBRA results are shown with undigested (U) PCR product next to digested (D) PCR product for
breast cancer cell lines and normal breast. (c) CoBRA results for breast tumour normal pairs. (d) DBC1 expression in normal breast tissue and re-
expression in methylated breast cancer cell line MDA-MB-231 following the addition of 5-aza-2’deoxycitidine is shown.
Hill et al. Molecular Cancer 2010, 9:51
http://www.molecular-cancer.com/content/9/1/51
Page 6 of 13of CIDE-A leads to caspase-independent cell death asso-
ciated with DNA fragmentation [17]. In addition, mice
lacking functional Cidea have higher metablic rates and
lipolysis in the brown adipose tissue as well as being
resistant to diet-induced obesity and diabetes as com-
pared to their wildtype littermates [18]. A recent report
indicates that CpG methylation plays a critical role in
determining tissue and cell specific expression of the
CIDE-A gene [10].
FBLN2 encodes for an extracelluar matrix protein,
belonging to a 6 member family of fibulins. FBLN2
binds various extracellular ligands and calcium. It acts
as a scaffold protein in the ECM by binding to a variety
of ligands including type IV collagen, fibronectin, fibri-
nogen, fibrillin, laminins, aggrecan and versican. It was
recently shown to be downregulated in breast cancer
cell lines and primary breast tumours. Reintroduction of
FBLN2 into breast cancer cell lines lacking FBLN2
reduced cell motility and invasion in vitro but had no
effect on cell growth and adhesion. Whilst, loss of
FBLN2 expression increased cell migration and invasion
[19]. Recently another member of the Fibulin gene
family, FBLN3 (EFEMP1) was shown to be frequently
methylated in breast tumours [20].
DBC1 (deleted in bladder cancer 1) was identified
from a common region of loss of heterozygosity at
9q32-q33 in bladder cancer. DBC1 has been shown to
be frequently methylated in bladder cancer, NSCLC,
oral cancer and acute lymphocytic leukemia [9,13-15].
Exogenous expression of DBC1 in NSCLC and in blad-
der cancer cell lines lacking DBC1 expression inhibited
cell growth [9,21]. It has also been demonstrated that
DBC1 plays a role in cell cycle control [21].
SALL1 is a human homologue of the Drosophila
region-specific homeotic gene spalt (sal). The SALL1
gene product is a zinc finger protein thought to act as a
transcription factor and maybe part of the NuRD his-
tone deacetylase complex. Mice lacking Sall1 die in the
perinatal period from kidney agenesis [22]. Townes-
Brocks syndrome affecting limb, ear, kidney and heart
Figure 5 Methylation analysis of FBLN2. (a) The region analysed by CoBRA and sequencing is shown with CpG dinucleotides numbered and
shown in bold and BstUI restriction sites underlined. The position of CoBRA primers is also shown, covering the region between -274 and +317
with respect to the transcription start site. (b) CoBRA results are shown with undigested (U) PCR product next to digested (D) PCR product for
breast cancer cell lines and normal breast. (c) CoBRA results for primary breast tumours. (d) CoBRA results for breast tumour normal pairs. (e)
FBLN2 expression in normal breast tissue and upregulation in methylated breast cancer cell line HCC1395 following the addition of 5-aza-
2’deoxycitidine is shown.
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[23]. SALL1 was recently demonstrated to be hyper-
methylated in acute lymphocytic leukemia [11].
It has been demonstrated that methylated genes often
reside in regions of chromosomal loss [2]. SALL1 resides
at 16q12.1- a region demonstrated to undergo loss of
heterozygosity (LOH) in breast, prostate, ovarian cancer
and in retinoblastoma [24,25]. EMILIN2 is located at
18p11.3 in a region showing LOH in NSCLC, CRC and
breast cancer [26]. FBLN2 is located at 3p25.1 in a
region well documented for allelic loss in renal cell car-
cinoma and breast cancer [27,28]. CIDE-A is located at
18p11.2 in a region showing allelic loss in esophageal
squamous cell carcinoma [29] and DBC1 was identified
from a region of frequent loss of hetrozygosity at 9q32-
33 in bladder cancer [30].
Breast cancer is a hormone dependent cancer. In
patients with breast cancer estrogen receptor (ER) status
is an important treatment and prognostic factor. The
response of breast cancer patients to endocrine therapy
Figure 6 Methylation analysis of CIDE-A. (a) The region analysed by CoBRA and sequencing is shown with CpG dinucleotides numbered and
shown in bold and BstUI restriction sites underlined. The positions of CoBRA primers are also shown, covering the region between -277 and -31
with respect to the transcription start site. (b) CoBRA results are shown with undigested (U) PCR product next to digested (D) PCR product for
breast cancer cell lines and normal breast. (c) CoBRA results for primary breast tumours. (d) CoBRA results for breast tumour normal pairs. (e)
Selected PCR products were cloned and sequenced. Individual alleles of each of the four samples shown are represented by a line, black and
white circles represent methylated and unmethylated CpG dinucleotides respectively. The frequency of methylation within the amplified region
for each sample is indicated by the methylation index (MI). (f) CIDE-A expression in normal breast tissue and re-expression in methylated breast
cancer cell line MBA-MD-231 following the addition of 5-aza-2’deoxycitidine is shown.
Table 1 Methylation frequencies in breast cancer
CIDE-A DBC1 EMILIN2 FBLN2 SALL1
Cell lines 7/8 (88%) 2/6 (34%) 5/9 (56%) 3/5 (60%) 4/6 (67%)
Tumours 21/40 (53%) 8/31 (26%) 16/36 (45%) 13/38 (34%) 25/40 (63%)
Matched pairs 7/15 (47%) 4/16 (25%) 4/10 (40%) 6/19 (32%) 10/20 (50%)*
Frequencies of methylation in breast cancer cell lines, primary breast tumours and matched breast tumour/normal pair samples are shown for EMILIN2, SALL1,
DBC1, FBLN2 and CIDE-A. All tumour/normal pair figures represent the number of pairs that show tumour specific methylation, (*) indicates that one of these
pairs also showed methylation in the corresponding normal.
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terone receptors. Breast cancers that are positive for
estrogen receptor and/or progesterone receptor respond
better to endocrine therapy compared to receptor nega-
tive breast cancers. Our findings indicate that methyla-
tion of EMILIN2, CIDE-A and FBLN2 are associated
with positive estrogen and or progesterone receptor sta-
tus, this may help in further refining breast cancers that
are more likely to benefit from endocrine therapy.
In our cohort of breast cancer cases, EMILIN2 methy-
lation also correlated with lymph node metastases,
relapse and poor survival, hence EMILIN2 methylation
is associated with less favourable prognosis. It will be of
interest to analyse larger sample numbers to determine
if EMILIN2 methylation status can be utilised as a prog-
nostic marker in breast cancer.
Conclusion
In summary we have identified 5 (EMILIN2, SALL1,
DBC1, FBLN2, CIDE-A) genes that demonstrated fre-
quent tumour acquired methylation in breast cancer. In
addition, EMILIN2 and SALL1 also show frequent methy-
lation in colorectal cancer and FBLN2 shows frequent
tumour-specific methylation in prostate cancer. Identifi-
cation of these methylated genes will help in elucidating
the pathology of the affected cancers and in developing
epigenetic markers across epithelial and other cancers.
Methods
Cancer cell lines and patient samples
Five breast cancer cell lines (HCC1806, HCC1419,
HCC1395, HCC1143 and HCC1937) and two normal
human mammary epithelial cell lines (NHMEC lines
1585T and 3736T) were used for MIRA. CoBRA analysis
used an additional four breast cancer cell lines (MCF7,
T47D, MDA-MB-231 and HTB19) and one normal
breast tissue DNA sample (AMS Biotechnology), repla-
cing the NHMEC lines. Cell lines were grown as
described previously [31,32]. Clinical and pathological
features of the breast cancer cell lines are described in
reference 31 and additional file 3. A set of 40 breast
tumours (ductal carcinomas) and an independent set of
further 20 breast tumours (ductal carcinomas) with cor-
responding normal breast tissue DNA were analysed.
Additional file 4 gives the clinical-pathological
Table 2 Methylation frequencies in lung, colorectal and
prostate cancers.
CIDE-A DBC1 EMILIN2 FBLN2 SALL1
Lung tumour lines 11/15 not done 4/10 7/9 4/13
Lung tumours 1/16 not done 1/13 0/11 4/16
Lung benign 0/16 not done 1/17 0/10 3/17
Colorectal tumour lines 8/8 8/8 4/5 4/4 6/6
Colorectal tumours 7/8 8/8 19/57 54/58 44/53
Colorectal adenomas 7/7 8/8 7/22 23/23 17/19
Colorectal benign 16/16 16/16 1/82 74/80 30/79
Prostate tumour lines 3/4 2/5 3/5 1/5 3/4
Prostate tumours 3/14 1/14* 0/14 5/14 5/14
Prostate benign 1/4 2/4* 0/4 0/4 1/4
Methylation frequencies are shown for lung, colorectal and prostate cancer
cell lines and primary tumours and normal tissue. (*) very weak methylation.
DBC1 methylation in lung cancer has been demonstrated previously, hence in
this study DBC1 was not analysed in lung cancer.
Figure 7 Methylation analysis of EMILIN2 in colorectal cancer. (a) COBRA results are shown with undigested (-) PCR product next to
digested (+) PCR product for matching normal (N) and colorectal carcinoma (C) in the upper panel and matching normal (N) and adenoma (A)
in the lower panel. (b) Selected PCR products were cloned and sequenced. Individual alleles of each of the four samples shown are represented
by a line, black and white circles represent methylated and unmethylated CpG dinucleotides respectively. The frequency of methylation within
the amplified region for each sample is indicated by the methylation index (MI).
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Ethical guidelines were followed for sample collection. A
cell line panel consisting of nine colorectal, fifteen lung
and five prostate cancer cell lines was used for initial
analyses in these cancers. Further work was then carried
out using colorectal adenomas and tumours, non small
cell lung carcinomas and prostate tumours together
with corresponding non cancerous tissue.
MIRA Assay
The MIRA assay was carried out on five breast cancer
cell lines (HCC1806, HCC1419, HCC1395, HCC1143
and HCC1937) and two normal mammary epithelial cell
lines (NHMEC lines 1585T and 3736T). The MIRA
assay and chip hybridisation procedure was carried out
as described previously in references 7 and 8. Human
CpG island microarrays containing 27800 CpG islands
covering 21 MB were purchased from Agilent
Technologies.
Candidate Selection
Methylation enrichment factors of tumour to normal
were calculated for all probes. This data was then ana-
lysed as follows:
￿ First selection, a single probe with a greater than
5-fold increase in MIRA-enriched fraction of tumour
versus normal in 3 or more cell lines. This selected
for 14,875 probes representing 6,912 individual hits.
￿ From these hits were removed any that did not
represent a known, named gene. This selection
removed 145 Open reading frames (Orfs), 3225
Chromosomal regions, 29 miRNAs, 143 Predicted
genes (LOCs, MGCs, FLJs and KIAs) and 23 Agilent
Plate related hits. This selection retained 3,347 genes
(10,840 probes) which represent a low stringency
candidate list.
￿ The low stringency candidate probe list was
further refined by the removal of all probes not
designated to be within promoter or divergent pro-
moter regions. This selection retained 3,352 probes
representing 1268 genes.
￿ Finally, a stricter selection criteria of a single probe
with a greater than 10-fold increase in 4 or more
cell lines was applied. This selection retained 895
probes representing 276 genes which represent a
high stringency candidate list (see additional file 1)
A large number of target genes were identified using
both approaches, particularly the low stringency
approach. The low stringency candidate list was com-
pared to a publically available expression array data for
an experiment demonstrating the re-expression of genes
in the MCF7 breast cancer cell line after treatment with
a de-methylating agent (GEO data base accession ID
GSE5816). Genes in both the low stringency candidate
list and the re-expressed list were then considered.
Functional annotation of target genes from both lists
was carried out using the functional annotation table
function in DAVID http://david.abcc.ncifcrf.gov[33,34].
Additional file 2 shows the results from this analysis for
the 32 target genes chosen to be analysed in this study.
We also carried out literature searches using Pubmed
http://www.ncbi.nlm.nih.gov/pubmed/ for the keywords
(breast cancer, Cancer & Methylation) and searched
SAGE expression data(GeneCards-http://www.genecards.
org/cgi-bin/cardsearch) and Oncomine https://www.
oncomine.org/. UCSC genome browser http://genome.
ucsc.edu/ was used to confirm the presence of CpG
islands within the likely promoter regions of genes.
Methylation analysis
Combined bisulphite restriction analysis (CoBRA) was
used to analyse all genes in this study. Bisulphite modifi-
cation of DNA was carried out as described previously
[35]. Semi-nested CoBRA primers were designed to
amplify specific regions within the CpG island close to
the start of transcription for all 32 genes (primer
sequences are shown in additional file 5 for the final 5
positive genes). Digestion of PCR products with BstUI
(CGCG) or TaqaI (TCGA) was carried out overnight at
37°C or 65°C respectively prior to visualisation on a 2%
agarose gel. In vitro methylated DNA was used as a
Figure 8 EMILIN2 survival analysis in breast tumours.K a p l a n
Meier survival analysis for EMILIN2 methylation status and relapse
free survival (P = 0.041).
Hill et al. Molecular Cancer 2010, 9:51
http://www.molecular-cancer.com/content/9/1/51
Page 10 of 13positive control. Confirmation of CoBRA results was
obtained by bisulphite sequencing. PCR products from
selected samples were cloned into the pGEM-T easy
vector (Promega) according to manufacturers’ instruc-
tions. Single colony PCR was carried out on up to 12
colonies for each cloned sample and methylation index
(MI) for each sample calculated as a percentage; number
of CpG dinucleotides methylated/total number of CpG
dinucleotides sequenced × 100.
Expression Analysis and 5-aza-2-deoxycitidine treatment
Cell lines were maintained in DMEM media (Sigma
Aldrich) supplemented with 10% FCS and 2 mM gluta-
mine at 37°, 5% CO2. Breast cancer cell lines HCC1806,
HCC1419, HCC1937, HCC1395, MCF7, HTB19, T47D
and MDA-MB-231 were treated with 5 μM 5-aza-2’-
deoxycitidine (5-aza-dC). Treatment was carried out
over 5 days with daily media changes and addition of
fresh 5-aza-dC. RNA bee (AMS biotechnology) was used
to extract RNA from 5-aza-dC treated and non-treated
cells. Control breast total RNA was bought from AMS
Biotechnology. cDNA was synthesised from 1 μgt o t a l
RNA using SuperScript III (Invitrogen) and random
hexamer primers. Touchdown PCR was used for expres-
sion analysis (primer sequences are shown in additional
file 6 for the final 5 positive genes). GAPDH analysis
was carried out concurrently for each gene using pri-
mers and PCR conditions described previously [35]. For
each gene we used 2 methylated and one unmethylated
cell line for expression analysis.
Real-time RT-PCR
Quantitative real-time RT-PCR was performed as
described previously [36]. Briefly, cDNA was made from
total RNA extracted from frozen normal and tumour
breast tissues. We quantified transcripts of the TBP
(TATA box-binding protein) gene as the endogenous
RNA control. Each sample was normalized on the basis
of TBP content. Results, expressed as N-fold differences
in target gene expression relative to the TBP gene
(termed Ntarget), were determined by the following for-
mula: Ntarget =2 Δ
Ctsample,w h e r et h eΔCt value of the
sample was determined by subtracting the average Ct
value of the target gene from the average Ct value of
Figure 9 EMILIN2 expression analysis in breast tumours. EMILIN2 mRNA expression is downregulated by promoter region hypermethylation
in breast tumours. EMILIN2 expression was detected by quantitative real-time RT-PCR in EMILIN2 unmethylated and methylated breast tumours
(Figure 2c shows the methylation status for some of these tumours). The averages for both unmethylated and methylated samples are also
shown and a t-test has been used to determine the statistical significance between the two (p = 0.018).
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subsequently normalized such that the mean ratio of the
normal breast samples would equal a value of 1. The
nucleotide sequences of the primers used for PCR
amplification were as follows: (a) EMILIN2-U (5’-
GCTTGAAGAAAGCCACAGATAATGAA-3’)a n d
EMILIN2-L (5’-CTGAGGCCCCTCTTTTGGATCTA-3’)
with a EMILIN2-specific product size of 116 bp, (b)
TBP-U (5’-TGCACAGGAGCCAAGAGTGAA-3’)a n d
TBP-L (5’-CACATCACAGCTCCCCACCA-3’)w i t ha
TBP-specific product size of 132 bp. PCR was performed
using the SYBR Green PCR Core Reagents kit (Perkin-
Elmer Applied Biosystems). The thermal cycling condi-
tions comprised an initial denaturation step at 95°C for
10 min and 50 cycles at 95°C for 15 s and 65°C for 1
min. Experiments were performed with duplicates for
each data point.
Statistical analysis
Methylation results were summarised using cross-tabula-
tions. Comparisons of methylation rates of genes within
t h es a m es a m p l ew e r ea n a l y s e du s i n gM c N e m a r ’st e s t s ,
and exact P-values were obtained. Comparisons of
methylation rates between normal and tumour cells were
analysed using chi-squared tests. Associations between
methylation status and clinicopathological characteristics
were assessed using a two-sample t-test for the continu-
ous variable age and chi-squared tests for categorical
variables. All analyses were conducted using Stata Ver-
sion 10.1 (Stata Corporation: College Station, TX, USA).
List of Abbreviations
MIRA: methylated-CpG island recovery assay; 5-aza-dC:
5-aza-2’deoxycytidine; COBRA: Combined Bisulphite
Restriction Analysis; NSCLC: non-small cell lung carci-
noma; CRC: colorectal cancer.
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Additional file 5: Methylation primers. CoBRA sequences and
annealing temperatures are shown for DBC1, CIDE-A, EMILIN2, FBLN2 and
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